ClinicalTrials.Veeva

Menu
G

Gastroenterology Associates of Central Georgia, LLC | Gastrointestinal Research and Clinical Trial Center of Georgia

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

CP-690,550
Risankizumab
ABT-494
Filgotinib
Upadacitinib
Vonoprazan
Budesonide
Lansoprazole
CC-93538
Lutikizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 32 total trials

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

This is a 24-week randomized, double-blind, placebo-controlled induction study of APT-1011 in adults (≥18 years old) with eosinophilic esophagitis (E...

Active, not recruiting
Eosinophilic Esophagitis
Procedure: Esophagogastroduodenoscopy
Drug: Placebo oral tablet

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

The study consists of 4 sub-studies, as follows:* Sub-study 1 (Randomized, double-blind, placebo controlled study) to evaluate the efficacy and safet...

Active, not recruiting
Crohn's Disease
Drug: Placebo for Risankizumab IV
Drug: Risankizumab SC

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Enrolling
Ulcerative Colitis
Drug: Adalimumab
Drug: Lutikizumab Matching Placebo
Locations recently updated

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Enrolling
Crohn's Disease
Drug: Placebo for risankizumab
Drug: Risankizumab SC

The purpose of this study is to evaluate safety and efficacy of risankizumab in participants with ulcerative colitis (UC) in participants who respond...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: placebo for risankizumab
Drug: risankizumab

This is a open-label extension (OLE) study designed to evaluate the long-term efficacy, safety, and tolerability of Upadacitinib (ABT-494).

Active, not recruiting
Crohn's Disease (CD)
Drug: ABT-494

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting
Ulcerative Colitis (UC)
Drug: Placebo
Drug: Upadacitinib (ABT-494)

To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.

Enrolling
Bowel; Stricture
Combination Product: GIE Medical ProTractX3 TTS DCB
Other: Control

To evaluate the safety and efficacy of the ProTractX3™ DCB for the treatment of benign esophageal strictures.

Enrolling
Esophageal Stricture
Other: Control
Combination Product: GIE Medical ProTractX3 TTS DCB

This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will e...

Enrolling
Eosinophilic Esophagitis
Drug: CC-93538

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankiz...

Active, not recruiting
Crohn's Disease (CD)
Drug: Risankizumab
Drug: Ustekinumab

This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the effi...

Active, not recruiting
Cirrhosis
Prevention of Esophageal Varices
Drug: belapectin
Drug: Placebo

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Enrolling
Ulcerative Colitis
Drug: ABBV-668

Trial sponsors

AbbVie logo
Pfizer logo
Shire logo
G
G
Gilead Sciences logo
Phathom Pharmaceuticals logo
Celgene logo
E
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems